je.st
news
Home
› Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment
Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment
2015-11-20 04:25:37| drugdiscoveryonline Home Page
Gurnet Point Capital, an investment firm focused on the healthcare and life sciences sectors that was founded by Ernesto Bertarelli and is led by Christopher A. Viehbacher, recently announced the creation of Boston Pharmaceuticals, a fully-integrated drug development company that will offer an innovative alternative model for drug development and commercialization.
Tags: company
point
development
capital
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||